Viking Therapeutics' Prospects in the Weight Loss Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.480
Low
70.00
Averages
97.00
High
125.00
Current: 37.480
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics Stock Price Analysis
- Stock Performance: Viking Therapeutics, Inc. ended the recent trading session at $37.48, reflecting a -3.92% change from the previous day, although this decline was less than the S&P 500's loss of 0.22%, indicating relative resilience in its stock performance.
- Monthly Gain: The company's shares have gained 33.19% over the past month, significantly outperforming the Medical sector's 6.47% increase, suggesting strong market performance and heightened investor confidence.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$1.21, representing a 108.62% decline from the same quarter last year, highlighting the company's profitability challenges and market concerns about its future performance.
- Analyst Rating: Currently, Viking Therapeutics holds a Zacks Rank of #4 (Sell), with its industry positioned in the bottom 37% of the Zacks Industry Rank, signaling overall industry weakness and caution for investors.
See More
Viking Therapeutics Shares Surge 27% with Promising Weight Loss Drug Trials
- Clinical Trial Progress: Viking Therapeutics' weight-loss candidate VK2735 is undergoing two phase 3 clinical trials, with results expected within 12 to 18 months, which could serve as a significant catalyst for stock price appreciation.
- Market Potential: VK2735 mimics the actions of both GLP-1 and GIP gut hormones, potentially offering better weight loss results than single GLP-1 drugs; positive trial outcomes could lead to a substantial stock price increase.
- Diversified Strategy: The company is also developing an oral formulation of VK2735, with plans to initiate phase 3 trials by year-end, aiming to expand market share and address shortcomings of existing weight-loss medications.
- Risks and Opportunities: While Viking Therapeutics faces risks inherent in clinical-stage biotech, strong phase 3 results could propel the stock to $100 within the next 18 months, attracting interest from risk-tolerant investors.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
Eli Lilly Stock Surges on Strong Drug Approvals and Market Position
- Stock Surge: Eli Lilly's stock has risen approximately 6.7% over the past week, driven by strong company-specific news and a broader rally in the U.S. drug and biotech sectors, reflecting market confidence in its growth prospects.
- Drug Approval Recommendation: The European Medicines Agency's Committee recommended approval of Lilly's Jaypirca for chronic lymphocytic leukemia treatment, which, if approved, would expand its indication in the EU, with a final decision expected in one to two months, potentially boosting revenue.
- Medicare Program Launch: Lilly announced its GLP-1 Bridge program, set to provide eligible Medicare Part D beneficiaries access to its oral GLP-1 drug Foundayo and injection Zepbound for $50 per month starting July 1, 2026, marking the first broad Medicare coverage for GLP-1 obesity medications.
- Market Leadership: Lilly maintains a strong position in the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, expected to benefit from rising global demand for GLP-1 therapies, despite challenges from price declines and increasing competition.
See More
Viking Therapeutics Stock Price Analysis
- Stock Performance: Viking Therapeutics, Inc. ended the recent trading session at $37.48, reflecting a -3.92% change from the previous day, although this decline was less than the S&P 500's loss of 0.22%, indicating relative resilience in its stock performance.
- Monthly Gain: The company's shares have gained 33.19% over the past month, significantly outperforming the Medical sector's 6.47% increase, suggesting strong market performance and heightened investor confidence.
- Earnings Forecast: The upcoming earnings report is expected to show an EPS of -$1.21, representing a 108.62% decline from the same quarter last year, highlighting the company's profitability challenges and market concerns about its future performance.
- Analyst Rating: Currently, Viking Therapeutics holds a Zacks Rank of #4 (Sell), with its industry positioned in the bottom 37% of the Zacks Industry Rank, signaling overall industry weakness and caution for investors.
See More
Viking Therapeutics Shares Surge 27% with Promising Weight Loss Drug Trials
- Clinical Trial Progress: Viking Therapeutics' weight-loss candidate VK2735 is undergoing two phase 3 clinical trials, with results expected within 12 to 18 months, which could serve as a significant catalyst for stock price appreciation.
- Market Potential: VK2735 mimics the actions of both GLP-1 and GIP gut hormones, potentially offering better weight loss results than single GLP-1 drugs; positive trial outcomes could lead to a substantial stock price increase.
- Diversified Strategy: The company is also developing an oral formulation of VK2735, with plans to initiate phase 3 trials by year-end, aiming to expand market share and address shortcomings of existing weight-loss medications.
- Risks and Opportunities: While Viking Therapeutics faces risks inherent in clinical-stage biotech, strong phase 3 results could propel the stock to $100 within the next 18 months, attracting interest from risk-tolerant investors.
See More
Viking Therapeutics' Prospects in the Weight Loss Drug Market
- Market Potential: The weight loss drug market is projected to reach nearly $100 billion in the coming years, presenting Viking Therapeutics with significant growth opportunities as a newcomer in a space dominated by Eli Lilly and Novo Nordisk.
- Clinical Trial Progress: Viking's lead candidate VK2735 is currently in phase 3 trials, with an oral version set to begin in Q4; positive data could significantly boost stock prices and attract investor interest.
- Pipeline Diversification: In addition to VK2735, Viking has launched a phase 1 trial for VK3019, representing a new strategy for obesity treatment, showcasing the company's diversity in drug development and potential for attracting partnerships.
- Risks and Challenges: Despite a 40% stock price increase over the past year, Viking faces stiff competition from giants like Eli Lilly and Novo Nordisk, and any failure of drug candidates could severely impact its market position, necessitating careful risk assessment by investors.
See More
Viking Therapeutics Stock Rises on Optimism for New Drug Developments
- Stock Surge: Viking Therapeutics' stock rose by 19.2% in June, according to S&P Global Market Intelligence, reflecting market optimism regarding its weight-loss drug pipeline, particularly the clinical trial progress of the new drug VK2735.
- Clinical Trial Progress: VK2735 demonstrated a steeper weight loss rate in Phase 2 trials and is currently undergoing Phase 3 trials; positive results could bolster investor confidence, with results expected in 2027 and 2028.
- Dual-Formulation Strategy: VK2735 is being developed as a dual-formulation therapy, with an initial injectable dose for rapid weight loss followed by an oral maintenance dose, and preliminary results from the ongoing maintenance trial are expected in Q3, potentially impacting future market performance.
- New Drug Development: Viking Therapeutics has also initiated a Phase 1 study of VK3019, representing a new class of drug with a different mechanism, showcasing the company's diversified potential in the weight-loss drug sector and enhancing market expectations for its future products.
See More
Viking's VK2735 Drug Shows Promising Outlook
- Clinical Trial Progress: Viking's VK2735 demonstrated a steeper weight loss rate in Phase 2 trials, leading to investor optimism for its Phase 3 results expected in 2027 and 2028, which could significantly boost the company's stock price.
- Dual-Formulation Advantage: As a dual-formulation therapy, VK2735's initial injectable dose aims for rapid weight loss, followed by an oral maintenance dose, potentially enhancing patient adherence and treatment efficacy, thus strengthening its market competitiveness.
- New Drug Development: Viking has also initiated a Phase 1 study for VK3019, a novel dual amylin and calcitonin receptor agonist, showcasing the company's diverse potential in the weight-loss drug sector, which may attract more investor interest.
- Positive Market Reaction: In June, Viking Therapeutics' stock rose by 19.2%, reflecting market optimism regarding its drug pipeline, particularly in innovative weight-loss solutions and potential returns.
See More
Eli Lilly Stock Surges on Strong Drug Approvals and Market Position
- Stock Surge: Eli Lilly's stock has risen approximately 6.7% over the past week, driven by strong company-specific news and a broader rally in the U.S. drug and biotech sectors, reflecting market confidence in its growth prospects.
- Drug Approval Recommendation: The European Medicines Agency's Committee recommended approval of Lilly's Jaypirca for chronic lymphocytic leukemia treatment, which, if approved, would expand its indication in the EU, with a final decision expected in one to two months, potentially boosting revenue.
- Medicare Program Launch: Lilly announced its GLP-1 Bridge program, set to provide eligible Medicare Part D beneficiaries access to its oral GLP-1 drug Foundayo and injection Zepbound for $50 per month starting July 1, 2026, marking the first broad Medicare coverage for GLP-1 obesity medications.
- Market Leadership: Lilly maintains a strong position in the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, expected to benefit from rising global demand for GLP-1 therapies, despite challenges from price declines and increasing competition.
See More
